These compounds may be useful for treating primary cancer, or for preventing metastatic disease in breast, lung, pancreatic, prostate, and other cancers. Unlike the parent compound, cyclopamine, and its previously-described derivatives, these steroid-derived analogs developed are simple to synthesize. They retain the effectiveness of cyclopamine as an anti-cancer agent.

PCT Application No. PCT/US2008/081704 (WO 2009/058945, published 05/07/2009); a U.S. application has been filed.

Wistar is seeking to collaborate with a corporate partner to use this technology to develop small molecule cancer therapies. An exclusive license or sponsored research to further develop the technology would be considered.